The latest in drug repurposing points to a double action for UV-blocking beta blockers @expbio #melanoma… https: //t.co/sJzYAhcoC3

The latest in drug repurposing points to a double action for UV-blocking beta blockers @expbio #melanoma… https://t.co/sJzYAhcoC3

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/856433593714868224
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

The latest in drug repurposing points to a double action for UV-blocking beta blockers @expbio #melanoma… https: //t.co/sJzYAhcoC3

Beta blocker shows cancer-fighting properties

A new study finds that carvedilol, a drug typically used to treat high blood pressure, can protect against the sun-induced cell damage that leads to skin cancer. Researchers serendipitously discovered the beta blocker’s cancer-fighting properties after…

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2olI2wO
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Beta blocker shows cancer-fighting properties

New bone-in technique tests therapies for breast cancer metastasis

A new laboratory technique developed by researchers at Baylor College of Medicine and other institutions can rapidly test the effectiveness of treatments for life-threatening breast cancer metastases in bone. The study appears in Nature…

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oCopwx
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

New bone-in technique tests therapies for breast cancer metastasis

#IMPAKT2017: Nicholas Turner @royalmarsden will speak about current clinical data for CDK 4/6 inhibitors… https://t.co/M6f2vsI7dA

#IMPAKT2017: Nicholas Turner @royalmarsden will speak about current clinical data for CDK 4/6 inhibitors… https://t.co/M6f2vsI7dA

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://twitter.com/ecancer/status/856398626322612224
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

#IMPAKT2017: Nicholas Turner @royalmarsden will speak about current clinical data for CDK 4/6 inhibitors… https://t.co/M6f2vsI7dA

Is prostate cancer different in black men? Answers from 3 natural history models

BACKGROUND

Black men in the United States have substantially higher prostate cancer incidence rates than the general population. The extent to which this incidence disparity is because prostate cancer is more prevalent, more aggressive, and/or more frequently diagnosed in black men is unknown.

METHODS

The authors estimated 3 independently developed models of prostate cancer natural history in black men and in the general population using an updated reconstruction of prostate-specific antigen screening, based on the National Health Interview Survey in 2005 and on prostate cancer incidence data from the Surveillance, Epidemiology, and End Results program during 1975 through 2000. By using the estimated models, the natural history of prostate cancer was compared between black men and the general population.

RESULTS

The models projected that from 30% to 43% (range across models) of black men develop preclinical prostate cancer by age 85 years, a risk that is (relatively) 28% to 56% higher than that in the general population. Among men who had preclinical disease onset, black men had a similar risk of diagnosis (range, 35%-49%) compared with the general population (32%-44%), but their risk of progression to metastatic disease by the time of diagnosis was from 44% to 75% higher than that in the general population.

CONCLUSIONS

Prostate cancer incidence patterns implicate higher incidence of preclinical disease and higher risk of metastatic progression among black men. The findings suggest screening black men earlier than white men and support further research into the benefit-harm tradeoffs of more aggressive screening policies for black men. Cancer 2017. © 2017 American Cancer Society.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oB9frx
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Is prostate cancer different in black men? Answers from 3 natural history models

Prostate cancer in black men: Is it time for personalized screening approaches?

Evidence is accumulating that a “1-size-fits-all” screening approach to prostate cancer may not be what is most appropriate. Therefore, the use of personalized screening approaches in higher risk men, particularly black men, warrants further policy consideration. See also pages 000-000.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2ok8FlL
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Prostate cancer in black men: Is it time for personalized screening approaches?

Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models

Meta-analytic data on the effect of coffee in prostate cancer risk are controversial. Caffeine as a bioactive compound of coffee has not yet been studied in deep in vitro. Our study aimed at evaluating in a population cohort the effect of Italian-style coffee consumption on prostate cancer risk and at investigating in vitro the potential antiproliferative and antimetastatic activity of caffeine on prostate cancer cell lines. 6,989 men of the Moli-sani cohort aged ≥50 years were followed for a mean of 4.24 ± 1.35 years and 100 new prostate cancer cases were identified. The European Prospective Investigation into Cancer and Nutrition-Food Frequency Questionnaire was used for the dietary assessment and the evaluation of Italian-style coffee consumption. Two human prostate cancer cell lines, PC-3 and DU145, were tested with increasing concentrations of caffeine, and their proliferative/metastatic features were evaluated. The newly diagnosed prostate cancer participants presented lower coffee consumption (60.1 ± 51.3 g/day) compared to the disease-free population (74.0 ± 51.7 g/day) (p < 0.05). Multiadjusted analysis showed that the subjects at highest consumption (>3 cups/day) had 53% lower prostate cancer risk as compared to participants at the lowest consumption (0–2 cups/day) (p = 0.02). Both human prostate cancer cell lines treated with caffeine showed a significant reduction in their proliferative and metastatic behaviors (p < 0.05). In conclusion, reduction by Italian-style coffee consumption of prostate cancer risk (>3 cups/day) was observed in epidemiological level. Caffeine appeared to exert both antiproliferative and antimetastatic activity on two prostate cancer cell lines, thus providing a cellular confirmation for the cohort study results.

from #Cancer-Sfakianakis via simeraentaxei on Inoreader http://ift.tt/2oB6I0G
via IFTTT Medicine by Alexandros G.Sfakianakis,Anapafseos 5 Agios Nikolaos,Crete 72100,Greece,tel :00302841026182 & 00306932607174

Reduction by coffee consumption of prostate cancer risk: Evidence from the Moli-sani cohort and cellular models